Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Oncology

• Publication date

  2015-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.59.7401PMID 25940717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.

  2014cited by this paper
• Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients

  2014cited by this paper
• Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

  2014cited by this paper
• High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions

  2013cited by this paper
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

  2013cited by this paper
• Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.

  2013cited by this paper
• Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?

  2013cited by this paper
• Correction

  2013cited by this paper
• The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

  2012cited by this paper
• ATM mutations in patients with hereditary pancreatic cancer.

  2012cited by this paper
• The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer

  2012cited by this paper
• Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience

  2012cited by this paper
• Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.

  2012cited by this paper
• International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

  2012cited by this paper
• Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment.

  2011cited by this paper
• Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling

  2011cited by this paper
• An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.

  2011cited by this paper
• Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

  2011cited by this paper
• Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated

  2011cited by this paper
• Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome

  2009cited by this paper
• BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.

  2009cited by this paper
• Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

  2009cited by this paper
• Genomic rearrangements in BRCA1 and BRCA2: A literature review

  2009cited by this paper
• Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer.

  2009cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer

  2007cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006cited by this paper
• Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• BRCA2 germline mutations in familial pancreatic carcinoma.

  2003cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

  2002cited by this paper
• Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.

  2001cited by this paper
• Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.

  2000cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

  1997cited by this paper
• Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients

  1997cited by this paper
• Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

  1996cited by this paper
• Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1995cited by this paper

• CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2–CCL2, CCR5–CCL5, CCR4–CCL17/22, CCR6–CCL20, CCR7–CCL19/21

  2026cites this paper
• Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.

  2026cites this paper
• [Oligometastasis in the gastrointestinal tract].

  2026cites this paper
• Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer

  2026cites this paper
• Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort

  2025cites this paper
• Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome.

  2025cites this paper
• Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case report and literature review

  2025cites this paper
• Genetic medicine of familial and hereditary pancreatic cancer: Recent update in the era of precision cancer medicine

  2025cites this paper
• Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?

  2025cites this paper
• Experimental models of pancreas cancer: what has been the impact for precision medicine?

  2025cites this paper
• Combination Therapy Using Phytochemicals and PARP Inhibitors in Hybrid Nanocarriers: An Optimistic Approach for the Management of Colon Cancer

  2025cites this paper
• Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects

  2025cites this paper
• Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview

  2025cites this paper
• Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy

  2025cites this paper
• Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort

  2025cites this paper
• Novel Therapies in Advanced Pancreatic Cancer: A Peak Beyond the Realms of Gene Targeting

  2025cites this paper
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy

  2025cites this paper
• Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

  2025cites this paper
• Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients

  2025cites this paper
• Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.

  2025cites this paper
• The Revolution in Germline DNA Testing: Actionable Takeaways from the 2023 Precision Oncology Summit

  2024cites this paper
• S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

  2024cites this paper
• Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

  2024cites this paper
• Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling

  2024cites this paper
• Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma

  2024cites this paper
• Organoid‐based precision medicine in pancreatic cancer

  2024influential citation
• Genomic Characterization of Preclinical Prostate Cancer Cell Line Models

  2024cites this paper
• Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience

  2024cites this paper
• Mutational profiling of 103 unresectable pancreatic ductal adenocarcinomas using EUS-guided fine-needle biopsy

  2024cites this paper
• Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer

  2024cites this paper
• Metastatic Pancreatic Cancer: Where Are We?

  2024cites this paper
• Prognostic significance of BRCA1 and BRCA2 methylation status in circulating cell-free DNA of Pancreatic Cancer patients

  2024cites this paper
• Understanding familial risk of pancreatic ductal adenocarcinoma

  2024influential citation
• Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.

  2024cites this paper
• Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

  2024cites this paper
• Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer

  2024cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma

  2024cites this paper
• Genome-wide analysis to assess if heavy alcohol consumption modifies the association between SNPs and pancreatic cancer risk.

  2024cites this paper
• Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy

  2024cites this paper
• Advances in immunotherapy and targeted therapy for pancreatic cancer

  2024cites this paper
• A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

  2024cites this paper
• Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake

  2023cites this paper
• Clinical Updates for Gastrointestinal Malignancies

  2023cites this paper
• Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan.

  2023cites this paper
• The Initial Journey of Patients with Metastatic Pancreatic Cancer (PaCTO Project): A Nationwide Survey among Portuguese Specialist Physicians

  2023cites this paper
• Successful treatment of GEMOX regimen combined with nimotuzumab in the pancreatic cancer with wild KRAS and mutant BRCA: a report of two cases

  2023cites this paper
• Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review

  2023cites this paper
• Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges

  2023cites this paper
• Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review

  2023cites this paper
• REV7 is involved in outcomes of platinum‐based chemotherapy in pancreatic cancer by controlling the DNA damage response

  2023cites this paper
• Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.

  2023cites this paper
• Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy

  2023cites this paper
• Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations

  2023cites this paper
• Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study

  2023cites this paper
• Therapeutic Targeting of Oncogene-induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Synergistic effects of resveratrol with gemcitabine in pancreatic cancer chemotherapy by inhibiting the c-Met/PARP1 axis

  2023cites this paper
• Screening for pancreatic cancer has the potential to save lives, but is it practical?

  2023cites this paper
• Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report

  2023cites this paper
• Pancreatic Cancer: BRCA Targeted Therapy and Beyond

  2023cites this paper
• Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer

  2023cites this paper
• The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer

  2023cites this paper
• A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing

  2023cites this paper
• Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?

  2023influential citation
• Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan

  2023cites this paper
• Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

  2023cites this paper
• Can Platinum Plus Gemcitabine be an Alternative to Folfirinox?

  2023cites this paper
• Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics—A Review

  2023cites this paper
• Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma

  2023cites this paper
• Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review

  2023cites this paper
• Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency

  2023cites this paper
• Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53.

  2023cites this paper
• Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine

  2023cites this paper
• The role of molecular testing in pancreatic cancer

  2023cites this paper
• BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

  2022cites this paper
• Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome

  2022cites this paper
• Integrated genomic analysis to identify druggable targets for pancreatic cancer

  2022cites this paper
• Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice

  2022cites this paper
• Traitement médical du cancer du pancréas

  2022cites this paper
• Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.

  2022cites this paper
• Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas

  2022cites this paper
• TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status

  2022cites this paper
• Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer

  2022influential citation
• Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.

  2022cites this paper
• Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity

  2022cites this paper
• The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

  2022cites this paper
• Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Pancreatic Cancer: Beyond Brca Mutations

  2022cites this paper
• Pancreatic mixed acinar–neuroendocrine carcinoma in a patient with a germline BRCA2 mutation: a case report

  2022cites this paper
• Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

  2022cites this paper
• Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

  2022cites this paper
• Targeting KRAS in PDAC: A New Way to Cure It?

  2022cites this paper
• Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Identification of high-risk germline variants for the development of pancreatic cancer: Common characteristics and potential guidance to screening guidelines.

  2022cites this paper
• Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.

  2022cites this paper
• Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.

  2022cites this paper
• SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021)

  2022cites this paper
• Identification of significant prognostic risk markers for pancreatic ductal adenocarcinoma: a bioinformatic analysis.

  2022cites this paper